These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34275328)

  • 1. Feasibility of singlicate-based analysis in bridging ADA assay on Meso-Scale Discovery platform: comparison with duplicate analysis.
    Jiang Z; Kamerud J; You Z; Basak S; Seletskaia E; Steeno GS; Gorovits B
    Bioanalysis; 2021 Jul; 13(14):1123-1134. PubMed ID: 34275328
    [No Abstract]   [Full Text] [Related]  

  • 2. European Bioanalysis Forum recommendation on singlicate analysis for ligand binding assays: time for a new mindset.
    Barfield M; Goodman J; Hood J; Timmerman P
    Bioanalysis; 2020 Mar; 12(5):273-284. PubMed ID: 31975612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
    Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
    J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
    Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
    AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An electrochemiluminescence (ECL)-based assay for the specific detection of anti-drug antibodies of the IgE isotype.
    Wu Y; Liu X; Chen Y; Woods R; Lee N; Yang H; Chowdhury P; Roskos LK; White WI
    J Pharm Biomed Anal; 2013 Dec; 86():73-81. PubMed ID: 23988731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.
    Wyant T; Yang L; Rosario M
    AAPS J; 2020 Nov; 23(1):3. PubMed ID: 33200296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Singlicate Ligand Binding Assay Using an Automated Microfluidic System: a Clinical Case Study.
    Jiang H; Kozhich A; Cummings J; Gambardella J; Zambito F; Titsch C; Haulenbeek J; Phillips K; Fergus R; Myler H
    AAPS J; 2017 Sep; 19(5):1461-1468. PubMed ID: 28589510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies.
    Zhong ZD; Jiang LL; Khandelwal P; Clarke AW; Bakhtiar R; Zou L
    AAPS J; 2020 Jan; 22(2):36. PubMed ID: 31997031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes.
    Shibata H; Nishimura K; Miyama C; Tada M; Suzuki T; Saito Y; Ishii-Watabe A
    J Immunol Methods; 2018 Jan; 452():73-77. PubMed ID: 28970009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies.
    Jyamubandi I; Aamir A; Kaur J; Sylvester A; Hughes R; Li S
    Bioanalysis; 2024 Jan; 16(1):5-17. PubMed ID: 37991214
    [No Abstract]   [Full Text] [Related]  

  • 13. A survey of applications of biological products for drug interference of immunogenicity assays.
    Wang YM; Fang L; Zhou L; Wang J; Ahn HY
    Pharm Res; 2012 Dec; 29(12):3384-92. PubMed ID: 22903525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new method for identification of outliers in immunogenicity assay cut point data.
    Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
    J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
    Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
    Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies.
    Niimi S; Nishimiya K; Nishidate M; Saito T; Minoura K; Kadotsuji K; Shimakura J; Shigemizu H; Hosogi J; Adachi M; Hashimoto T; Mori T; Harada H; Yamamoto KI; Nakamura T; Nomura T; Yamaguchi I; Sonehara K; Ishii-Watabe A; Kawasaki N
    Drug Metab Pharmacokinet; 2018 Apr; 33(2):125-132. PubMed ID: 29610053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.
    Goodman J; Cowen S; Devanarayan V; Egging D; Emrich T; Golob M; Kramer D; McNally J; Munday J; Nelson R; Pedras-Vasconcelos JA; Piironen T; Sickert D; Skibeli V; Fjording MS; Timmerman P
    Bioanalysis; 2018 Feb; 10(4):197-204. PubMed ID: 29345496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.